NAD+ and Cellular Aging: From Mechanism to Human Evidence

NAD+ holds a central place in cell biology. That mechanistic importance has sometimes been turned into a shortcut: NAD+ supposedly falls mechanically with age, so raising it should slow aging. Human evidence calls for a more rigorous reading.

A molecule can be indispensable to a biological pathway without an increase in its blood concentration demonstrating a health benefit. Understanding the NAD+ file requires separating mechanism, target engagement, and clinical benefit.

NAD+: a central coenzyme

Nicotinamide adenine dinucleotide, or NAD+, participates in redox reactions that help convert nutrients into energy cells can use. It also serves as a substrate for several enzyme families, including sirtuins and PARPs (poly-ADP-ribose polymerases), involved in cellular regulation and DNA repair (PubMed).

These functions explain the scientific interest in NAD+ metabolism. They do not establish that a higher blood concentration automatically improves function, prevents disease, or extends lifespan.

With age, different trajectories across tissues

Part of the narrative about “NAD+ decline” comes from animal models and analyses conducted in specific tissues. In mice, research has described disrupted communication between the nucleus and mitochondria when nuclear NAD+ falls (PubMed). Other animal experiments have linked CD38 activity to lower NAD+ in certain tissues with age (PubMed).

These findings illuminate plausible mechanisms. They do not demonstrate a uniform decline, quantified in the same way, across every human tissue between two given ages.

In 2026, a study across seven independent human cohorts directly examined the signal in whole blood. The authors observed no variation in NAD+ with either age or the lifestyle interventions studied. They therefore challenge its use as a blood biomarker of aging or lifestyle (PubMed).

This result does not prove that NAD+ remains unchanged in every organ throughout life. It does rule out two generalizations: presenting a uniform blood decline as established, or treating a blood NAD+ measurement as a validated reflection of aging across all tissues.

NR: an engaged target, not a demonstrated benefit

Nicotinamide riboside (NR) is an NAD+ precursor. Its ability to raise blood NAD+ is well documented. In an eight-week randomized trial of 140 overweight but otherwise healthy adults, 100 and 300 mg of NR per day raised whole-blood NAD+ by 22% and 51% after two weeks. Those increases were maintained during the trial (PubMed).

This response confirms NR exposure and engagement of the intended biological pathway. The trial does not establish that higher blood NAD+ improves health: its primary purpose concerned safety and metabolism, not the demonstration of a clinical benefit.

Another trial administered 1,000 mg per day for 21 days to twelve older men. The skeletal-muscle NAD+ metabolome changed, without an observed improvement in mitochondrial bioenergetics or systemic metabolism (PubMed). The finding illustrates the potential gap between a biochemical change and a functional effect.

Why blood NAD+ is not a benefit in itself

A biomarker can replace a clinical outcome only when it has been validated as a surrogate endpoint for the conclusion being drawn. In other words, changing it must predict, with adequate reliability, an outcome that matters to the person: improved function, reduced clinical risk, or another defined health result.

Whole-blood NAD+ currently has no such validation for the longevity benefits attributed to NR. Raising it proves that the molecule acts on its biochemical target; it proves neither that the relevant tissues benefit nor that the change produces a clinical outcome.

The full reasoning and the other excluded molecules are detailed in our exclusions dossier.

What biomarkers can — and cannot — tell us

NAD+ is not measured in routine clinical blood panels. More importantly, no standard combination of oxidative stress, inflammation, or mitochondrial-function markers can indirectly reconstruct an individual's “NAD+ need” or calibrate an NR dose.

Those markers may be useful for their own indications. They should not be repurposed to validate an intervention whose benefit has not been established. The right question is therefore not only “does NR raise NAD+?” but “does that increase improve a relevant health outcome in the population, at the dose, and for the use under consideration?”

For NR at 100–300 mg per day in the intended general population, the first answer is yes. The second remains unproven. That distinction — not a lack of interest in NAD+ biology — underpins the current exclusion.

Frequently asked questions

What is NAD+ and why is it important?#[ + ]

NAD+ (nicotinamide adenine dinucleotide) participates in the reactions that allow cells to produce energy. It is also a substrate for sirtuins and PARPs, enzyme families involved in processes including the stress response and DNA repair. This central biological role does not mean that raising blood NAD+ is itself a health benefit.

Does NAD+ necessarily decline with age?#[ + ]

No uniform decline has been demonstrated across all compartments. Tissue and preclinical studies describe decreases in some settings. By contrast, an analysis of seven human cohorts found stable whole-blood NAD+ concentrations across age and lifestyle interventions. Tissue, measurement method, and study population therefore matter greatly.

Is nicotinamide riboside effective in humans?#[ + ]

At 100 and 300 mg per day, nicotinamide riboside does raise whole-blood NAD+: it engages its biological target. Available data do not, however, demonstrate a proportionate clinical benefit at those doses in the intended general population. Whole-blood NAD+ has not been validated as a surrogate endpoint for such a benefit either.

Can a standard blood panel be used to calibrate NR intake?#[ + ]

No. NAD+ is not measured in standard clinical practice, and markers of oxidative stress, inflammation, or mitochondrial function are not validated substitutes from which an individual need for NR can be inferred. They may have clinical value in their own right, but they demonstrate neither NAD+ deficiency nor the relevance of supplementation.

Why does Singular exclude NR?#[ + ]

An increase in NAD+ shows that NR reaches its biological target; on its own, it does not demonstrate a human benefit. For the evaluated use — 100 to 300 mg per day in the intended general population — NR clears the bioavailability filter but fails the human clinical evidence filter. This decision does not settle research using higher doses in selected pathological populations.

---

References

1. Covarrubias AJ, Perrone R, Grozio A, Verdin E. NAD+ metabolism and its roles in cellular processes during ageing. Nat Rev Mol Cell Biol. 2021;22(2):119-141 (PubMed).
2. Gomes AP, et al. Declining NAD(+) induces a pseudohypoxic state disrupting nuclear-mitochondrial communication during aging. Cell. 2013;155(7):1624-1638 (PubMed).
3. Camacho-Pereira J, et al. CD38 dictates age-related NAD decline and mitochondrial dysfunction through an SIRT3-dependent mechanism. Cell Metab. 2016;23(6):1127-1139 (PubMed).
4. Trętowicz MM, Scantlebery AML, Schomakers BV, et al. Human whole-blood NAD+ levels do not vary with age or lifestyle interventions. Nat Metab. 2026;8(6):1282-1290 (PubMed).
5. Conze D, Brenner C, Kruger CL. Safety and metabolism of long-term administration of NIAGEN (nicotinamide riboside chloride) in a randomized, double-blind, placebo-controlled clinical trial of healthy overweight adults. Sci Rep. 2019;9(1):9772 (PubMed).
6. Elhassan YS, Kluckova K, Fletcher RS, et al. Nicotinamide riboside augments the aged human skeletal muscle NAD+ metabolome and induces transcriptomic and anti-inflammatory signatures. Cell Rep. 2019;28(7):1717-1728.e6 (PubMed).